+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
NOVELIX NOVELIX

Novelix Pharmaceuticals Share Price

₹75.80 +2.08 (2.82%)
99.47% Gain from 52W Low

07 Aug, 2026 4:00 PM (IST)

Novelix Pharmaceuticals live price: ₹75.80. It opened at ₹75 vs previous close ₹74; intraday high/low: ₹77/₹70. The 50 & 200 DMA stand at ₹69.20/₹58.90.

Novelix Pharmaceuticals Performance

  • Today's Low
  • ₹70
  • Today's High
  • ₹77
  • 52 Week Low
  • ₹38
  • 52 Week High
  • ₹92
  • Open Price₹75
  • Previous Close₹74
  • Volume8,916
  • 50 DMA₹69.20
  • 100 DMA₹65.60
  • 200 DMA₹58.90

Novelix Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 9.06%
  • Over 3 Month + 38.96%
  • Over 6 Month + 18.9%
  • Over 1 Year + 80.48%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 52.2
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 134
  • P/B Ratio
  • 3.1
  • Average True Range
  • 4.5
  • EPS
  • 1.5
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 50.43
  • MFI
  • 53.89

Latest Stock News Updates

Novelix Pharmaceuticals Ltd - 536565 - Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On 13Th August, 2026.

Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Submission of prior Intimation of Board meeting.

Novelix Pharmaceuticals Ltd - 536565 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Submission of Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018

Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vupparapalli Chandrasekhar Reddy & Others

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹75.80
+ 2.08 (2.82%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹70.60
  • 50 Day
  • ₹69.20
  • 100 Day
  • ₹65.60
  • 200 Day
  • ₹58.90

Resistance and Support

74.3 Pivot Speed
  • R3 82.00
  • R2 79.50
  • R1 75.10
  • S1 68.20
  • S2 65.70
  • S3 61.30

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-06-04 Preferential Issue of shares & Others Inter-alia, to consider 1. Approve the Draft Notice of EGM. 2.Fix the day, date, time & venue of EGM. 3. Appoint Scrutinizer for conducting E- voting process for EGM. 4. Other business matters.
2026-05-29 Audited Results & Preferential issue
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
Date Purpose Remarks
2010-10-05 Split Consolidation of Shares from Re. 1/- to Rs. 10/-
2009-10-16 Split Stock Split from Rs. 10/- to Re. 1/-.

Novelix Pharmaceuticals Shareholding Pattern

50.57%
49.43%
0%

About Novelix Pharmaceuticals

Novelix Pharmaceuticals is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. View More
  • NSE Symbol
  • NOVELIX
  • BSE Symbol
  • 536565
  • ISIN
  • INE314I01036

Similar Stocks to Novelix Pharmaceuticals

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹75 As on 10 August, 2026 | 06:33

The Market Cap of Novelix Pharmaceuticals is ₹133.5 Cr As on 10 August, 2026 | 06:33

The P/E ratio of Novelix Pharmaceuticals is 52.2 As on 10 August, 2026 | 06:33

The PB ratio of Novelix Pharmaceuticals is 3.1 As on 10 August, 2026 | 06:33

The 52 week High & Low of Novelix Pharmaceuticals is ₹92/₹38 respectively As on 10 August, 2026 | 06:33

Open FREE Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23